Treatment of consecutive patients with chronic myeloid
leukaemia in the cooperating centres from the Czech Republic
and the whole of Slovakia after 2000 – a report from the
population-based CAMELIA Registry

J 2011

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry

FABER, Edgar; Jan MUŽÍK; Vladimír KOZA; Eva DEMEČKOVÁ; Jaroslava VOGLOVÁ et al.

Základní údaje

Originální název

Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry

Autoři

Vydání

European Journal of Haematology, 2011, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.614

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00052700

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1111/j.1600-0609.2011.01637.x

UT WoS

000292778800008

Klíčová slova anglicky

chronic myeloid leukaemia; imatinib; tyrosine kinase inhibitors; allogeneic stem cell transplantation; interferon; registry

Příznaky

Mezinárodní význam

Změněno: 23. 3. 2012 13:31, Mgr. Michal Petr

Anotace

V originále

Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow-up was 46.1 months (0–122.2). Results: Most patients were treated with first- (379; 57.3%) or second-line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic-phase patients treated with first-line imatinib, second-line imatinib and first-line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression-free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly.

Citovat

FABER, Edgar; Jan MUŽÍK; Vladimír KOZA; Eva DEMEČKOVÁ; Jaroslava VOGLOVÁ; Ludmila DEMITROVIČOVÁ; Juraj CHUDEJ; Imrich MARKULJAK; Eduard CMUNT; Tomáš KOZÁK; Elena TÓTHOVÁ; Marie JAROŠOVÁ; Ladislav DUŠEK a Karel INDRÁK. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. European Journal of Haematology. 2011, roč. 87, č. 2, s. 157-168. ISSN 0902-4441. Dostupné z: https://doi.org/10.1111/j.1600-0609.2011.01637.x.

@article{945635,
   author = {Faber, Edgar and Mužík, Jan and Koza, Vladimír and Demečková, Eva and Voglová, Jaroslava and Demitrovičová, Ludmila and Chudej, Juraj and Markuljak, Imrich and Cmunt, Eduard and Kozák, Tomáš and Tóthová, Elena and Jarošová, Marie and Dušek, Ladislav and Indrák, Karel},
   article_number = {2},
   doi = {https://doi.org/10.1111/j.1600-0609.2011.01637.x},
   keywords = {chronic myeloid leukaemia; imatinib; tyrosine kinase inhibitors; allogeneic stem cell transplantation; interferon; registry},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry},
   volume = {87},
   year = {2011}
}

TY  - JOUR
ID  - 945635
AU  - Faber, Edgar - Mužík, Jan - Koza, Vladimír - Demečková, Eva - Voglová, Jaroslava - Demitrovičová, Ludmila - Chudej, Juraj - Markuljak, Imrich - Cmunt, Eduard - Kozák, Tomáš - Tóthová, Elena - Jarošová, Marie - Dušek, Ladislav - Indrák, Karel
PY  - 2011
TI  - Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry
JF  - European Journal of Haematology
VL  - 87
IS  - 2
SP  - 157-168
EP  - 157-168
SN  - 09024441
KW  - chronic myeloid leukaemia
KW  - imatinib
KW  - tyrosine kinase inhibitors
KW  - allogeneic stem cell transplantation
KW  - interferon
KW  - registry
N2  - Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow-up was 46.1 months (0–122.2). Results: Most patients were treated with first- (379; 57.3%) or second-line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic-phase patients treated with first-line imatinib, second-line imatinib and first-line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression-free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly.
ER  -

FABER, Edgar; Jan MUŽÍK; Vladimír KOZA; Eva DEMEČKOVÁ; Jaroslava VOGLOVÁ; Ludmila DEMITROVIČOVÁ; Juraj CHUDEJ; Imrich MARKULJAK; Eduard CMUNT; Tomáš KOZÁK; Elena TÓTHOVÁ; Marie JAROŠOVÁ; Ladislav DUŠEK a Karel INDRÁK. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. \textit{European Journal of Haematology}. 2011, roč.~87, č.~2, s.~157-168. ISSN~0902-4441. Dostupné z: https://doi.org/10.1111/j.1600-0609.2011.01637.x.

Přehled o publikaci